Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
This is a multicenter study phase II, open-label for cardiopathic patients affected by
 Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to
 study the feasibility of R-COMP in this cohort of patients.
Inclusion Criteria:

 -  NHL histological diagnosis of diffuse large B cell CD20 + (de novo or shift from
 low-grade NHL if not pretreated), grade IIIb follicular NHL;

 -  Age >= 18 years;

 -  Presence of at least 1 factor that defines the cardiopathy;

 -  Life expectancy > 3 months;

 -  In the case of women of childbearing age absence of pregnancy at the beginning of the
 chemotherapy;

 -  Written informed consent.

 Exclusion Criteria:

 -  Histology different from NHL diffuse large cell CD20 + or follicular IIIb

 -  Age < 18 years

 -  Inability to sign informed consent;

 -  HIV positivity;

 -  Patients HBsAg positive;

 -  AST/ALT > 2 times the standard;

 -  Bilirubin > 2 times the standard;

 -  Creatinine > 2.5 mg / dl;

 -  Location of CNS disease;

 -  Pregnancy ongoing;

 -  Damage to that organ or medical problems that could interfere with the therapy;

 -  Current uncontrolled infection;

 -  Senile dementia